Shivam Singh1, Anoop Saraya, Rinu Sharma. 1. University School of Biotechnology, Guru Gobind Singh Indraprastha University, Sector-16(c), Dwarka, New Delhi, 110078, India.
Abstract
BACKGROUND: Present-day diagnostic modalities for detecting periampullary carcinoma are suboptimal, and currently used proven markers lack specificity and sensitivity. METHODS: In order to assess the diagnostic potential of sperm protein 17, a cancer testis antigen, quantitative real-time PCR was performed to evaluate the expression of sperm protein 17 in tissue and sera specimens collected from periampullary carcinoma patients and normal subjects. Additionally, circulating levels of anti-sperm protein 17 antibodies were determined in sera of periampullary carcinoma patients and normal subjects using ELISA. RESULTS: Aberrant expression of sperm protein 17 was found in 14/15 (93 %) periampullary cancer tissues when compared with distant matched nonmalignant tissues (P = 0.006, Mann-Whitney U test). None of the distant matched nonmalignant tissues showed increased expression of sperm protein 17 mRNA. Area under the curve, sensitivity, and specificity were 0.791, 87, and 73 %, respectively. Increased levels of sperm protein 17 mRNA were demonstrated in sera of periampullary carcinoma patients (P = 0.020, Student's t test). Circulating levels of anti-sperm protein 17 antibody were found to be significantly elevated in 27/30 (90 %) periampullary carcinoma patients (P < 0.001, Student's t test). Area under the curve, sensitivity, and specificity were 0.954, 86.7, and 96.3 %, respectively. Only two of the normal subjects (7 %) showed elevated levels of anti-sperm protein 17 antibody. CONCLUSION: For the first time, our findings suggest that high levels of sperm protein 17 mRNA as well as increased circulating anti-sperm protein 17 antibodies can be used to distinguish periampullary cancer patients from healthy individuals, highlighting the diagnostic potential of sperm protein 17.
BACKGROUND: Present-day diagnostic modalities for detecting periampullary carcinoma are suboptimal, and currently used proven markers lack specificity and sensitivity. METHODS: In order to assess the diagnostic potential of sperm protein 17, a cancer testis antigen, quantitative real-time PCR was performed to evaluate the expression of sperm protein 17 in tissue and sera specimens collected from periampullary carcinomapatients and normal subjects. Additionally, circulating levels of anti-sperm protein 17 antibodies were determined in sera of periampullary carcinomapatients and normal subjects using ELISA. RESULTS: Aberrant expression of sperm protein 17 was found in 14/15 (93 %) periampullary cancer tissues when compared with distant matched nonmalignant tissues (P = 0.006, Mann-Whitney U test). None of the distant matched nonmalignant tissues showed increased expression of sperm protein 17 mRNA. Area under the curve, sensitivity, and specificity were 0.791, 87, and 73 %, respectively. Increased levels of sperm protein 17 mRNA were demonstrated in sera of periampullary carcinomapatients (P = 0.020, Student's t test). Circulating levels of anti-sperm protein 17 antibody were found to be significantly elevated in 27/30 (90 %) periampullary carcinomapatients (P < 0.001, Student's t test). Area under the curve, sensitivity, and specificity were 0.954, 86.7, and 96.3 %, respectively. Only two of the normal subjects (7 %) showed elevated levels of anti-sperm protein 17 antibody. CONCLUSION: For the first time, our findings suggest that high levels of sperm protein 17 mRNA as well as increased circulating anti-sperm protein 17 antibodies can be used to distinguish periampullary cancerpatients from healthy individuals, highlighting the diagnostic potential of sperm protein 17.
Authors: Sylvia Adams; David W O'Neill; Daisuke Nonaka; Elizabeth Hardin; Luis Chiriboga; Kimberly Siu; Crystal M Cruz; Angelica Angiulli; Francesca Angiulli; Erika Ritter; Rose Marie Holman; Richard L Shapiro; Russell S Berman; Natalie Berner; Yongzhao Shao; Olivier Manches; Linda Pan; Ralph R Venhaus; Eric W Hoffman; Achim Jungbluth; Sacha Gnjatic; Lloyd Old; Anna C Pavlick; Nina Bhardwaj Journal: J Immunol Date: 2008-07-01 Impact factor: 5.422
Authors: Fabio Grizzi; Maurizio Chiriva-Internati; Barbara Franceschini; Klaus Bumm; Piergiuseppe Colombo; Michele Ciccarelli; Elena Donetti; Nicoletta Gagliano; Paul L Hermonat; Robert K Bright; Magda Gioia; Nicola Dioguardi; W Martin Kast Journal: J Histochem Cytochem Date: 2004-04 Impact factor: 2.479